Literature DB >> 11516455

Molecular basis for the relationship between thrombosis and cancer.

F R Rickles1, A Falanga.   

Abstract

Cancer patients are highly susceptible to thromboembolic complications, which some have estimated accounts for a significant percentage of the morbidity and mortality of the disease. Not all of the mechanisms for the production of the hypercoagulable state characteristic of cancer are entirely understood. Those that are known seem to interdigitate the biology of cancer with the major regulatory pathways that mediate blood coagulation, platelet-vessel wall interaction, fibrinolysis and inflammatory cytokine production. In other words, the events responsible for thrombosis in cancer appears to be a result of an over exuberant host response in an attempt to delimit tumor growth. In this brief review, therefore, we attempt to put into the context of tumor growth, angiogenesis and metastasis the current information about the pathogenesis of venous thromboembolism (VTE).

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11516455     DOI: 10.1016/s0049-3848(01)00285-7

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  68 in total

1.  Roles of vimentin and 14-3-3 zeta/delta in the inhibitory effects of heparin on PC-3M cell proliferation and B16-F10-luc-G5 cells metastasis.

Authors:  Yan Pan; Li-jun Zhong; Hong Zhou; Xin Wang; Kui Chen; Hao-peng Yang; Yilixiati Xiaokaiti; Aikebaier Maimaiti; Ling Jiang; Xue-jun Li
Journal:  Acta Pharmacol Sin       Date:  2012-06       Impact factor: 6.150

2.  Androgen deprivation and thromboembolic events in men with prostate cancer.

Authors:  Behfar Ehdaie; Coral L Atoria; Amit Gupta; Andrew Feifer; William T Lowrance; Michael J Morris; Peter T Scardino; James A Eastham; Elena B Elkin
Journal:  Cancer       Date:  2011-11-09       Impact factor: 6.860

3.  Inhibition of tissue factor by ixolaris reduces primary tumor growth and experimental metastasis in a murine model of melanoma.

Authors:  Andreia Da Silva de Oliveira; Luize G Lima; Andréa Mariano-Oliveira; Daniel E Machado; Luiz E Nasciutti; John F Andersen; Lars C Petersen; Ivo M B Francischetti; Robson Q Monteiro
Journal:  Thromb Res       Date:  2012-06-09       Impact factor: 3.944

Review 4.  Trousseau's syndrome: multiple definitions and multiple mechanisms.

Authors:  Ajit Varki
Journal:  Blood       Date:  2007-05-11       Impact factor: 22.113

5.  Associations of factor VIIIc, D-dimer, and plasmin-antiplasmin with incident cardiovascular disease and all-cause mortality.

Authors:  Aaron R Folsom; Joseph A C Delaney; Pamela L Lutsey; Neil A Zakai; Nancy S Jenny; Joseph F Polak; Mary Cushman
Journal:  Am J Hematol       Date:  2009-06       Impact factor: 10.047

6.  Selectin-mucin interactions as a probable molecular explanation for the association of Trousseau syndrome with mucinous adenocarcinomas.

Authors:  Mark Wahrenbrock; Lubor Borsig; Dzung Le; Nissi Varki; Ajit Varki
Journal:  J Clin Invest       Date:  2003-09       Impact factor: 14.808

Review 7.  Biomolecular markers of cancer-associated thromboembolism.

Authors:  Diana L Hanna; Richard H White; Ted Wun
Journal:  Crit Rev Oncol Hematol       Date:  2013-03-21       Impact factor: 6.312

8.  Cancer-associated thrombosis.

Authors:  Mehran Karimi; Nader Cohan
Journal:  Open Cardiovasc Med J       Date:  2010-02-23

Review 9.  The potential benefits of low-molecular-weight heparins in cancer patients.

Authors:  Francisco Robert
Journal:  J Hematol Oncol       Date:  2010-01-14       Impact factor: 17.388

10.  Long-term activation of the pro-coagulant response after neoadjuvant chemoradiation and major cancer surgery.

Authors:  M Byrne; J V Reynolds; J S O'Donnell; M Keogan; B White; M Byrne; S Murphy; S G Maher; G P Pidgeon
Journal:  Br J Cancer       Date:  2009-12-01       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.